What is Verastem?
Verastem, Inc. is a biopharmaceutical company focused on the discovery and development of novel drug candidates aimed at improving outcomes for cancer patients. The company's lead programs include Duvelisib, a dual inhibitor of PI3K-Delta and PI3K-Gamma, which has shown promise in hematological malignancies and is undergoing further clinical evaluation. Additionally, Verastem is developing defactinib, a FAK inhibitor, in combination with immunotherapeutic agents across various cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer, and mesothelioma. These candidates are designed to modulate the tumor microenvironment, bolster anti-tumor immunity, and reduce cancer stem cells, positioning Verastem at the forefront of targeted cancer therapy development.
How much funding has Verastem raised?
Verastem has raised a total of $599M across 14 funding rounds:
Stock Offering
$63.3M
Unspecified
$2M
Other Financing Round
$3.9M
Stock Offering
$50.9M
Stock Offering
$25M
Multiple Rounds
$131.1M
Debt
$4.8M
Share Placement
$100M
Debt
$150M
Stock Issuance/Offering (2012): $63.3M featuring Undisclosed
Unspecified (2012): $2M backed by Undisclosed
Other Financing Round (2014): $3.9M with participation from Undisclosed
Stock Issuance/Offering (2015): $50.9M led by Undisclosed
Stock Issuance/Offering (2017): $25M supported by Undisclosed
Debt (2018): $50M featuring Hercules Capital
Stock Issuance/Offering (2018): $38.3M backed by Undisclosed
Stock Issuance/Offering (2018): $42.8M with participation from Consonance Capital
Debt (2020): $4.8M led by Undisclosed
Share Placement (2020): $100M supported by Vivo Capital, Farallon Capital Management, Logos Capital, EcoR1 Capital, Venrock Healthcare Capital Partners, Acuta Capital, Avidity Partners, and RA Capital Management
Debt (2022): $150M featuring Oxford Finance
Key Investors in Verastem
Vivo Capital
Vivo Capital, founded in 1996 and headquartered in Palo Alto, California, is a global healthcare investment firm with a focus on private and public equity, as well as venture capital.
Farallon Capital Management
Farallon Capital Management, established in 1986 and based in California, is an investment management company that manages discretionary equity capital from institutional investors, specializing in various asset classes.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, and diagnostics.
What's next for Verastem?
The substantial enterprise-level capital infusion and recent strategic investment provide Verastem with the necessary resources to accelerate its clinical development programs and potentially bring its promising oncology treatments to market. This backing is critical for navigating the complex and lengthy process of drug approval, including late-stage clinical trials and regulatory submissions. The company's focus on innovative mechanisms of action, such as targeting PI3K and FAK pathways, suggests a strategic approach to addressing unmet needs in cancer care. Future growth will likely depend on successful clinical trial outcomes and effective commercialization strategies, supported by continued investor confidence and strategic partnerships.
See full Verastem company page
